🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Full-Course ECMO Strategy for Moderate-to-Severe ARDS

RecruitingNAAges 18 Years - anyAllSoutheast University, China
NCT07726953 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

China faces major challenges in the ECMO management of patients with moderate-to-severe ARDS, including substantial heterogeneity in clinical practice, low weaning success rates, and high complication rates. A key underlying reason is the lack of a standardized full-course management pathway that is applicable to real-world clinical practice in China. This study focuses on the construction and evidence-based evaluation of a precision full-course ECMO management pathway for patients with moderate-to-severe ARDS, aiming to address fragmented care processes and delayed quality improvement. The study includes three main components. First, multidisciplinary consensus and evidence-based findings will be integrated to develop a standardized management pathway covering the full chain of assessment, initiation, maintenance, weaning, and rehabilitation. Second, a nationwide multicenter real-world

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 1\. Age 18 years or older. 2. Diagnosed with moderate-to-severe acute respiratory distress syndrome according to the global definition of ARDS. Exclusion Criteria: \- 1. Patients with tracheostomy before screening. 2. Patients who have received lung transplantation or are receiving venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation. 3\. Patients with cardiogenic shock requiring venoarterial ECMO or venoarterial-venous ECMO support.
💊

What it tests

  • Full-Course ECMO Management Pathway
  • Usual Care
📍

Where

39 sites
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
The Second Hospital of Jilin University
Changchun, China
West China Tianfu Hospital, Sichuan University
Chengdu, China
The First People's Hospital of Chenzhou
Chenzhou, China
The Second Affiliated Hospital of Dalian Medical University
Dalian, China
Fuzhou University Affiliated Provincial Hospital
Fuzhou, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Affiliated Hangzhou First People's Hospital of Westlake University School of Medicine
Hangzhou, China

…and 31 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy